A Phase 3 clinical trial by U.S.-based pharmaceutical companies Moderna and Merck has shown positive results for a personalized mRNA cancer vaccine in treating high-risk melanoma when combined with standard immunotherapy.
The experimental therapy, intismeran autogene (mRNA-4157/V940), improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared to pembrolizumab (Keytruda) alone.
This trial is notable as it demonstrates the first positive outcomes for an individualized neoantigen therapy and mRNA-based cancer treatment in this setting.
The study involved 1,137 patients with resected stage IIB to stage IV melanoma. Patients received either the personalized vaccine alongside pembrolizumab or pembrolizumab alone.
Safety data from the INTerpath-001 trial aligned with previous studies, showing no new safety issues.
Despite skepticism regarding mRNA technology, experts highlight its unique personalized approach compared to preventive COVID-19 vaccines.
The promising Phase 3 results may lead to market authorization discussions while ongoing concerns about mRNA technology's long-term safety remain.
No comments:
Post a Comment